Cargando…
M48. IS METABOLIC SYNDROME RELATED TO COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA? RESULTS FROM A DOUBLE-BLIND, ACTIVE-CONTROLLED, LURASIDONE STUDY
BACKGROUND: Schizophrenia is associated with cognitive dysfunction as well as cardiovascular disease (CVD). A central risk factor for CVD is the metabolic syndrome (MetS), which is of special concern in schizophrenia. The prevalence of MetS in U.S. patients with schizophrenia is higher versus genera...
Autores principales: | Hagi, Katsuhiko, Nosaka, Tadashi, Pikalov, Andrei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234130/ http://dx.doi.org/10.1093/schbul/sbaa030.360 |
Ejemplares similares
-
S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
por: Hagi, Katsuhiko, et al.
Publicado: (2020) -
T28. BENEFITS AND HARMS OF ANTIPSYCHOTICS IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2020) -
M43. MODEL-BASED ANALYSIS OF EFFECTS OF LURASIDONE ON PROLACTIN IN SCHIZOPHRENIA PATIENTS
Publicado: (2020) -
M84. METFORMIN FOR EARLY CO-MORBID PREDIABETES OR DIABETES IN SCHIZOPHRENIA SPECTRUM DISORDERS: A DOUBLE BLIND RANDOMIZED PILOT STUDY
por: Mahavir Agarwal, Sri, et al.
Publicado: (2020) -
M64. ADDRESSING THE ROLE OF TIMING ON COGNITION IN SCHIZOPHRENIA
por: Alústiza, Irene, et al.
Publicado: (2020)